67.97 0.00 (0.00%)
After hours: 4:10PM EST
|Bid||64.94 x 600|
|Ask||75.00 x 100|
|Day's range||67.83 - 69.78|
|52-week range||63.01 - 93.50|
|PE ratio (TTM)||19.55|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||78.44|
The Melville, New York-based company said it had a loss of 6 cents per share. Earnings, adjusted for pretax expenses and non-recurring costs, were 97 cents per share. The results matched Wall Street expectations. ...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Henry Schein, Inc. .
Antitrust allegations are sending shares of Patterson and Henry Schein down in a big way, and trouble for these companies doesn’t end there.
Henry Schein (HSIC), which is a distributor of healthcare products and services, was among the S&P 500’s top losers on February 13. Following a weak performance for two weeks, Henry Schein started this week on a mixed note and fell to three-month low price levels on Tuesday. The selling pressure in Henry Schein increased on Tuesday amid reports of a lawsuit.
Stocks closed the day with modest gains, as Under Armour soared on strong international sales, and dental suppliers Henry Schein and Patterson Companies were dinged by antitrust allegations.
Bragar Eagel & Squire, P.C. is investigating potential claims against Henry Schein, Inc. . Our investigation concerns whether Henry Schein has violated the federal securities laws and/or engaged in other unlawful business practices.
Holzer & Holzer, LLC is investigating whether Henry Schein, Inc. complied with the federal securities laws. On February 12, 2018, the FTC announced that it had filed a complaint against three dental supply companies, including Henry Schein, alleging that the companies violated U.S.
Levi & Korsinsky announces it has commenced an investigation of Henry Schein, Inc. concerning possible violations of federal securities laws.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of Henry Schein, Inc. resulting from allegations that Henry Schein may have issued materially misleading business information to the investing public.
Abraham, Fruchter & Twersky, LLP is investigating claims on behalf of investors of Henry Schein Incorporated .
Align Technology (ALGN) increased its expenditure toward consumer marketing by 60% in 2017. The increase in Invisalign treatment adoption rates across the teen and adult segments are driven by the company’s consumer marketing and sales initiatives. Peers Dentsply Sirona (XRAY), Zimmer Biomet Holdings (ZBH), and Henry Schein (HSIC) expect to post SG&A (selling, general, and administrative) expenses of 37.0%, 38.0%, and 20.0%, respectively, in their recent fiscal years.
On December 20, 2017, Align Technology announced the termination of its Invisalign interoperability contract with 3Shape. Effective January 31, 2018, Align Technology will not accept digital scans from 3Shape’s TRIOS scanners in the US for new treatment and retention cases of Invisalign aligners. Align Technology stated that the interoperability contract termination is due to the infringing conduct of 3Shape and the litigation against the company by Align Technology.
Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.
Investors need to pay close attention to Henry Schein (HSIC) stock based on the movements in the options market lately.